Nearly 30 years ago, researchers stumbled upon two unusual molecules in rye pollen that seemed to slow tumor growth in animals. But then they hit a wall: nobody could figure out the molecules' exact 3D structures. Cue the chemists at Northwestern University, who have now built secalosides A and B from scratch in the lab, confirming their structures for the first time.

With this molecular blueprint in hand, scientists can finally investigate how these rye pollen compounds - yes, from the same stuff that makes your pumpernickel bread possible - interact with the immune system. The hope is that this could pave the way for new cancer treatments. The findings were published in the Journal of the American Chemical Society.

"In preliminary studies, other researchers found that rye pollen could help different animal models clear tumors through some unknown, non-toxic mechanism," said Northwestern's Karl A. Scheidt, who led the study. "Now that we confirmed the structure of these molecules, we can find the active ingredient - or what part of the molecule is doing the work. This is an exciting starting point."

Nature has a solid track record here: morphine from poppies, Taxol from yew trees, statins from fungi. Rye pollen might join that club. It's already sold as a dietary supplement for prostate health, but pharmaceutical development stalled because no one could pin down the molecular structure.

The tricky part? The molecules contain a rare, highly strained 10-membered ring. The Northwestern team got around this by first making a larger, more flexible ring, then triggering a chemical reaction to shrink it into the strained configuration in one step. After synthesizing both possible versions, they compared them to natural rye pollen extracts. Only one matched.

"We've demonstrated we can make the core of this natural product," Scheidt said. "Now, we're trying to find potential collaborators in immunology who could help us translate this to a possible clinical endpoint."